Q-omics provides the consensus-scored SPACA6 profile across patient tissues and cancer cell-line models. SPACA6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPACA6 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, SPACA6 RNA expression shows 17,049 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where SPACA6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPACA6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPACA6 survival associations across molecular data types. SPACA6 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPACA6 RNA expression–survival associations across cancer types. High SPACA6 expression shows unfavorable associations in KIRC, UCEC, LUSC, UVM, KIRP and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPACA6 RNA expression.
This table summarizes SPACA6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SPACA6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPACA6 shows lower tumor expression in KICH, LUAD, KIRP and UCEC and higher tumor expression in CHOL and HNSC. The KICH box plot shows higher SPACA6 RNA expression in normal versus tumor tissue (log2 FC = −1.156, t-test p < 0.001).
This table shows molecular features associated with SPACA6 in patient tissues and cancer cell lines. In patient samples, SPACA6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPACA6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
